Economic Outcomes of Eszopiclone Treatment in Insomnia and Comorbid Major Depressive Disorder

被引:0
|
作者
Snedecor, Sonya J. [1 ]
Botteman, Marc F. [1 ]
Schaefer, Kendyl [2 ]
Sarocco, Phillip [2 ]
Barry, Nadine [2 ]
Pickard, A. Simon [3 ]
机构
[1] Pharmerit N Amer LLC, Bethesda, MD 20814 USA
[2] Sepracor Inc, Marlborough, MA USA
[3] Univ Illinois, Coll Pharm, Ctr Pharmacoecon Res, Chicago, IL USA
来源
关键词
QUALITY-OF-LIFE; COST-EFFECTIVENESS ANALYSIS; WORK PRODUCTIVITY; HEALTH; DISCONTINUATION; FLUOXETINE; RECOVERY; INDEX; SLEEP; SF-12;
D O I
暂无
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Eszopiclone is effective for the treatment of insomnia in patients with insomnia and comorbid major depressive disorder (MDD). Both conditions impose significant economic burden, with the US societal cost of depression estimated at $50 billion annually. Aims of the Study: The purpose of this analysis was to examine the costs and benefits of eszopiclone co-administered with fluoxetine (ESZ+FLX) compared to placebo co-administered with fluoxetine (PBO+FLX) in adults meeting the DSM-IV criteria for insomnia and MDD. Methods: Data from 434 patients enrolled in an 8-week clinical trial who met the economic-subanalysis criteria were examined. The costs of medical care (in 2007 US$) and lost work time were estimated from the Hamilton Depression Scale (HAM-D17) scores using published algorithms. Cost of lost productivity while at work was based on responses to the Work Limitations Questionnaire. The impact of therapy on quality-adjusted life years (QALYs) was estimated by transforming HAM-D17 (base case analysis) or Short Form Health Survey (SF-12) (scenario analyses) responses into health utility scores using published algorithms. Drug costs were estimated based on average wholesale price. Results: The mean 8-week increases in QALYs from baseline were 0.0392 and 0.0334 for the ESZ+FLX and PBO+FLX groups, respectively. Mean per-patient costs were $1,279 and $1,198 for the respective groups. Thus, co-treatment resulted in net increases of 0.0058 QALYs and $81, leading to an incremental cost per QALY gained of approximately $14,000. Discussion and Limitations: Co-administration of eszopiclone and fluoxetine improved patients' insomnia symptoms and appeared to be a cost-effective treatment strategy for patients with insomnia and comorbid MDD. One limitation of this study is that optimal utility estimation techniques were not available. Utilities were instead derived indirectly using the HAM-D17 (disease-specific, not generic) or SF-12 (generic, but potentially insensitive to important changes in some conditions) instruments. Implications for Health Care Provision: Sleep disturbance is predictive of depression relapse, and is the most common residual symptom in patients who have been successfully treated with fluoxetine for depression. Thus, identifying cost-effective strategies for the treatment of insomnia symptoms is important for this patient population. Implications for Health Policies: Treatment guidelines and drug coverage decisions should be based on clinical evidence, effectiveness, and economic criteria (i.e., whether an effective drug therapy produces sufficient benefits given its costs). This information about the overall value of eszopiclone can be measured as the cost per QALY gained with the use of ESZ+FLX compared with FLX alone. In order to make decisions based on value, payers and policy makers must have access to reliable cost-effectiveness information. Implications for Further Research: The residual efficacy observed in the clinical trial following the discontinuation of co-therapy should be explored further to determine whether intermittent treatment with ESZ+FLX is a cost-effective strategy.
引用
收藏
页码:27 / 35
页数:9
相关论文
共 50 条
  • [1] ECONOMIC OUTCOMES OF CO-TREATMENT OF INSOMNIA AND MAJOR DEPRESSIVE DISORDER (MDD) WITH ESZOPICLONE AND FLUOXETINE VERSUS FLUOXETINE TREATMENT ALONE
    Snedecor, S. J.
    Botteman, M. F.
    Schaefer, K.
    Sarocco, P.
    Barry, N.
    Pickard, A. S.
    [J]. VALUE IN HEALTH, 2008, 11 (06) : A586 - A586
  • [2] Adjunctive eszopiclone and fluoxetine in major depressive disorder and insomnia: Effects on sleep and depression
    Corrigan, M
    McCall, WV
    Fava, M
    Rubens, R
    Wessel, T
    Caron, J
    Amato, D
    Roth, T
    [J]. NEUROPSYCHOPHARMACOLOGY, 2005, 30 : S104 - S105
  • [3] Adjunctive eszopiclone and fluoxetine in major depressive disorder and insomnia: Effects on sleep and depression
    Bowler, K
    Rubens, R
    Wessel, T
    Caron, J
    Amato, D
    McCall, WV
    Fava, M
    Roth, T
    [J]. NEUROLOGY, 2006, 66 (05) : A78 - A78
  • [4] Sleep outcomes following eszopiclone discontinuation in patients with primary insomnia and insomnia co-existing with major depressive disorder or generalized anxiety disorder
    Krystal, A.
    Fava, M.
    Pollack, M.
    Rubens, R.
    Schaefer, K.
    Amato, D.
    Roth, T.
    [J]. SLEEP, 2007, 30 : A245 - A245
  • [5] Assessment of Suvorexant and Eszopiclone as Alternatives to Benzodiazepines for Treating Insomnia in Patients With Major Depressive Disorder
    Shigetsura, Yuki
    Imai, Satoshi
    Endo, Hiroki
    Shimizu, Yumi
    Ueda, Keita
    Murai, Toshiya
    Itohara, Kotaro
    Nakagawa, Shunsaku
    Yonezawa, Atsushi
    Ikemi, Yasuaki
    Fukatsu, Sachio
    Kitada, Noriaki
    Terada, Tomohiro
    Nakagawa, Takayuki
    Matsubara, Kazuo
    [J]. CLINICAL NEUROPHARMACOLOGY, 2022, 45 (03) : 52 - 60
  • [6] Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder
    Fava, M
    McCall, WV
    Krystal, A
    Wessel, T
    Rubens, R
    Caron, J
    Amato, D
    Roth, T
    [J]. BIOLOGICAL PSYCHIATRY, 2006, 59 (11) : 1052 - 1060
  • [7] DAYTIME INSOMNIA SYMPTOMS NEGATIVELY PREDICT ANHEDONIA IN PATIENTS WITH COMORBID MAJOR DEPRESSIVE DISORDER AND INSOMNIA DISORDER
    Osorno, R. A.
    Kaplan, K.
    Krystal, A.
    Buysse, D.
    Edinger, J.
    Manber, R.
    [J]. SLEEP, 2018, 41 : A361 - A362
  • [8] Evaluation of the Hamilton depression scale following eszopiclone treatment for insomnia in patients with insomnia co-morbid with major depressive disorder or generalized anxiety disorder
    Fava, Maurizio
    Pollack, Mark
    Rubens, Robert
    Amato, David
    Krystal, Andrew
    Hayduk, Roza
    McCall, W. Vaughn
    [J]. BIOLOGICAL PSYCHIATRY, 2007, 61 (08) : 84S - 84S
  • [9] Evaluation of the Hamilton depression scale following eszopiclone treatment for insomnia in patients with insomnia co-morbid with major depressive disorder or generalized anxiety disorder
    Fava, M.
    Pollack, M.
    Rubens, R.
    Amato, D.
    Kostal, A.
    Hayduk, R.
    McCall, W.
    [J]. SLEEP, 2007, 30 : A329 - A330
  • [10] Differential sleep effects of eszopiclone treatment and discontinuation in patients with primary insomnia and insomnia co-existing with major depressive disorder or generalized anxiety disorder
    Krystal, A.
    Schaefer, K.
    Rockett, C.
    Fava, M.
    Amato, D.
    Roth, T.
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 306 - 306